Skip to main content
Premium Trial:

Request an Annual Quote

Affy Stock Climbs 5 Percent as Investment Banks Continue Upgrades

NEW YORK, Oct. 3 (GenomeWeb News) - Shares in Affymetrix were up 5.2 percent, or $2.40, at $48.63 in mid-afternoon trading today after the company received its third upgrade from investment banks in the last week.


Earlier today, investment bank Leerink Swan upgraded Affy's stock to "outperform" from "market perform." On Friday, Lehman Brothers upgraded Affy's stock to "equal-weight" from "underweight."


The upgrades follow last week's upgrade by investment bank Robert W. Baird to "neutral" from "underperform."


The upgrades come in the wake of last week's disclosure that "low initial-production yields" of the company's 500K Mapping Array Set will result in a revenue shortfall in the third quarter of as much as 13 percent.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.